Location History:
- Baden, CH (2014)
- Windisch, CH (2016)
Company Filing History:
Years Active: 2014-2016
Title: **Inventor Ursula Püntener: Pioneering Advances in Antigen Binding Molecules**
Introduction
Ursula Püntener is a notable inventor based in Windisch, Switzerland, recognized for her contributions to the field of biotechnology. With a total of two patents to her name, she has significantly impacted the development of therapeutic agents that leverage the immune system to combat diseases, particularly through her work with monoclonal antibodies.
Latest Patents
Ursula's latest patents include innovative technologies related to polynucleotides encoding anti-CD20 antigen binding molecules. This invention focuses on nucleic acids that encode recombinant monoclonal antibodies that are specifically tailored for human CD20. These advancements feature isolated polynucleotides that enable the production of antibodies with enhanced binding affinity to Fc receptors and improved therapeutic properties. The patents also encompass methods for generating these antigen binding molecules (ABMs) and include systems for their practical application in treating diseases.
Career Highlights
Ursula Püntener is affiliated with Roche Glycart AG, an esteemed organization in the biopharmaceutical sector, where she contributes to cutting-edge research and product development. Her work continues to push the boundaries of antibody technology, striving to enhance the efficacy and safety of new treatments for patients.
Collaborations
Throughout her career, Ursula has collaborated with several talented professionals, including her coworkers Pablo Umaña and Peter Brünker. These partnerships have fostered a collaborative environment that allows for the exchange of innovative ideas and the fostering of groundbreaking research, ultimately enhancing the therapeutic potential of her inventions.
Conclusion
Ursula Püntener's work embodies the spirit of innovation within the biotechnology sector. Her patents not only signify a technological advancement but also hold the promise of improving therapeutic outcomes for patients through enhanced monoclonal antibody therapies. As she continues her journey at Roche Glycart AG, her contributions are set to make a lasting impact in the medical field.